<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anti-inflammatory and immunosuppressive drugs potentially useful in the treatment of pericardial disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anti-inflammatory and immunosuppressive drugs potentially useful in the treatment of pericardial disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Anti-inflammatory and immunosuppressive drugs potentially useful in the treatment of pericardial disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="10%"></colgroup><colgroup width="30%"></colgroup><colgroup width="10%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Pregnancy category*</td> <td class="subtitle1">Transplacental passage</td> <td class="subtitle1">Teratogenicity</td> <td class="subtitle1">Potential fetal-neonatal adverse effects</td> <td class="subtitle1">Long-term effects offspring</td> <td class="subtitle1">Fertility impairment</td> </tr> <tr class="divider_bottom"> <td>Aspirin (analgesic dosed) and non-selective NSAIDs</td> <td> <p>C (1st, 2nd T)</p> D (3rd T)</td> <td>Yes</td> <td>Yes</td> <td>No pattern of birth defects established; can be used safely during 1st and 2nd trimesters. Use in late pregnancy avoided due to concerns over possible effects on ductus arteriosus and renal function; refer to topic discussion. Rare adverse reports (eg, cardiac defects, gastroschisis, low birth weight) might be exposure related (all T).</td> <td>Unknown (none detected with low dose aspirin)</td> <td>Case descriptions of follicle rupture inhibition associated with prolonged use. May increase risk of spontaneous abortion if used at time of conception.</td> </tr> <tr class="divider_bottom"> <td>Celecoxib</td> <td> <p>C (1st, 2nd T)</p> D (3rd T)</td> <td>Expected</td> <td> <p>Unknown (human)</p> Yes (animal)</td> <td>Unknown. Interferes with embryonic development in rats and rabbits. Avoid during pregnancy.</td> <td>Unknown</td> <td>Unknown. Interferes with fertility in murine models.</td> </tr> <tr class="divider_bottom"> <td>Short-acting glucocorticoids (prednisone, prednisolone, methylprednisolone)</td> <td> <p>D (1st T)</p> C (2nd, 3rd T)</td> <td>Yes</td> <td>Yes</td> <td>May increase risk of orofacial clefting (1st T) and restrict fetal growth (all T). Hypoadrenalism may occur in neonate. Most data are reassuring when used at low to medium doses (ie, 10 to 20 mg orally per day).</td> <td>None detected</td> <td>Experience does not suggest impairment.</td> </tr> <tr class="divider_bottom"> <td>Colchicine</td> <td>C</td> <td>Yes</td> <td> <p>No (human)</p> Yes (animal)</td> <td>Colchicine should not be used in pregnancy beyond compelling maternal indication (ie, FMF). It is generally tapered before conception and substituted with aspirin and/or low dose prednisone.</td> <td>Unknown</td> <td>Experience in women does not suggest impairment. Rarely associated with infertility in men.</td> </tr> <tr class="divider_bottom"> <td>Azathioprine</td> <td>D</td> <td>Yes</td> <td> <p>No (human)</p> Yes (animal)</td> <td>Reports of hematologic abnormalities, immune impairment, growth restriction, and prematurity may be exposure related. May be rarely used in selected cases in pregnancy.</td> <td>Unknown</td> <td>Experience does not suggest impairment. May interfere with efficacy of intrauterine contraceptive devices.</td> </tr> <tr class="divider_bottom"> <td>Methotrexate</td> <td>X</td> <td>Yes</td> <td>Yes</td> <td>Spectrum defects include skull, facial feature, and limb anomalies when exposed during organogenesis (1st T). CNS abnormalities also reported. Growth retardation and mortality may be elevated in 2nd and 3rd T exposure. Use in pregnancy is absolutely contraindicated.</td> <td>Developmental delay and intellectual impairment reported</td> <td>Oligospermia in men and amenorrhea in women when used for cancer chemotherapy in combination with other agents.</td> </tr> <tr class="divider_bottom"> <td>Cyclophosphamide</td> <td>D</td> <td>Yes</td> <td>Yes</td> <td>Skeletal, palate, ocular, and limb defects associated with exposure during 1st T. 2nd and 3rd T exposure associated with smaller risk of malformations but hematologic abnormalities and growth restriction reported may be exposure related. Use in pregnancy is absolutely contraindicated.</td> <td>Unknown</td> <td>Gonadal toxicity established in dosage regimens for cancer chemotherapy.</td> </tr> <tr class="divider_bottom"> <td>Cyclosporine</td> <td>C</td> <td>Yes</td> <td>No</td> <td>Experience, based on limited case reports, does not establish an increased risk of birth defects. Reports of growth restriction, miscarriage, and preterm delivery may be exposure related. May be rarely used in selected cases during pregnancy.</td> <td>Unknown</td> <td>Experience does not suggest impairment.</td> </tr> <tr> <td>Intravenous immunoglobulins (IVIG)</td> <td>C</td> <td>Yes</td> <td>No</td> <td>Experience does not suggest an increased risk of congenital anomalies or other adverse embryonic effects. May be rarely used in selected cases in pregnancy.</td> <td>Unknown</td> <td>Unknown</td> </tr> </tbody></table></div><div class="graphic_footnotes">T: trimester of pregnancy; NSAID: nonsteroidal anti-inflammatory drug; FMF: familial Mediterranean fever; CNS: central nervous system.<br/>* Description of the US Food &amp; Drug Administration (FDA) pregnancy risk categories is provided in a separate table available in UpToDate. In 2015, US FDA began overseeing the phase-out of pregnancy risk categories (A, B, C, D, and X ) from prescription drug labeling and began requiring information from available human and animal studies of (1) known or potential maternal or fetal adverse reactions, and (2) dose adjustments needed during pregnancy and the postpartum period. Additional information is available at the US FDA website: <a href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm" target="_blank">Pregnancy and Lactation Labeling Final Rule</a>.</div><div class="graphic_reference">Data from:

<ol>
<li>Briggs GG, Freeman RK. Drugs in pregnancy and lactation 10th ed. Â©2015 Wolters Kluwer Health, Philadelphia PA. </li>
<li>United States FDA approved product information. http://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed November 25, 2014).</li>
</ol></div><div id="graphicVersion">Graphic 52475 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
